MX2015016451A - Compuestos heterocíclicos como inhibidores de la ruta de señalización hedgehog. - Google Patents

Compuestos heterocíclicos como inhibidores de la ruta de señalización hedgehog.

Info

Publication number
MX2015016451A
MX2015016451A MX2015016451A MX2015016451A MX2015016451A MX 2015016451 A MX2015016451 A MX 2015016451A MX 2015016451 A MX2015016451 A MX 2015016451A MX 2015016451 A MX2015016451 A MX 2015016451A MX 2015016451 A MX2015016451 A MX 2015016451A
Authority
MX
Mexico
Prior art keywords
signaling pathway
heterocyclic compounds
pathway inhibitors
hedgehog signaling
compounds
Prior art date
Application number
MX2015016451A
Other languages
English (en)
Inventor
Inder Bhamra
Armer Richard
Bingham Matilda
Mccarroll Andrew
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Publication of MX2015016451A publication Critical patent/MX2015016451A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos novedosos de fórmula (I); los compuestos de la invención son antagonistas de la ruta Hedgehog. Específicamente, los compuestos de la invención son útiles como inhibidores de Smoothened (SMO); la invención también contempla el uso de los compuestos para el tratamiento de afecciones tratables mediante la inhibición de la ruta de señalización Hedgehog y SMO, por ejemplo el cáncer.
MX2015016451A 2013-05-28 2014-05-28 Compuestos heterocíclicos como inhibidores de la ruta de señalización hedgehog. MX2015016451A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1309508.8A GB201309508D0 (en) 2013-05-28 2013-05-28 Compounds
PCT/GB2014/051623 WO2014191737A1 (en) 2013-05-28 2014-05-28 Heterocyclic compounds as hedgehog signaling pathway inhibitors

Publications (1)

Publication Number Publication Date
MX2015016451A true MX2015016451A (es) 2016-08-03

Family

ID=48784788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016451A MX2015016451A (es) 2013-05-28 2014-05-28 Compuestos heterocíclicos como inhibidores de la ruta de señalización hedgehog.

Country Status (17)

Country Link
US (1) US9579319B2 (es)
EP (1) EP3004078A1 (es)
JP (1) JP2016520115A (es)
KR (1) KR20160013188A (es)
CN (1) CN105431421A (es)
AU (1) AU2014272867A1 (es)
BR (1) BR112015029495A2 (es)
CA (1) CA2912208A1 (es)
EA (1) EA201592108A1 (es)
GB (1) GB201309508D0 (es)
HK (1) HK1217492A1 (es)
IL (1) IL242515A0 (es)
MX (1) MX2015016451A (es)
PH (1) PH12015502611A1 (es)
SG (1) SG11201509580PA (es)
WO (2) WO2014191737A1 (es)
ZA (1) ZA201508396B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
US10464897B2 (en) * 2015-06-05 2019-11-05 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
KR20230109185A (ko) 2016-06-07 2023-07-19 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CA3029086C (en) * 2016-07-04 2021-02-16 Suzhou Kintor Pharmaceuticals, Inc. Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof
CN106474147B (zh) * 2016-10-14 2022-07-05 上海颉隆投资管理有限公司 一种预防和控制人乳头状瘤病毒感染的敷料及其制备方法
JP6878615B2 (ja) 2017-03-23 2021-05-26 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
WO2018211007A1 (en) 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
CN109734700B (zh) * 2019-01-14 2021-09-28 中国药科大学 含苯甲酰哌啶结构的smo抑制剂及其制备方法与用途
CA3226995A1 (en) 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567725A (en) * 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4022779A (en) 1974-07-25 1977-05-10 E. R. Squibb & Sons, Inc. Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters
GB1513432A (en) * 1974-07-25 1978-06-07 Squibb & Sons Inc Pyridopyrazines
WO1997026258A1 (en) 1996-01-15 1997-07-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
AU732129B2 (en) * 1997-06-24 2001-04-12 Janssen Pharmaceutica N.V. Angiogenesis inhibiting thiadiazolyl pyridazine derivatives
BRPI0512902A (pt) 2004-06-30 2008-04-15 Janssen Pharmaceutica Nv derivados de ftalazina como inibidores de parp
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
WO2009020137A1 (ja) * 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アミノピラゾールアミド誘導体
BRPI0911618A2 (pt) * 2008-04-29 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de ftalazina dissubstituída.
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
FR2938537B1 (fr) * 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
CN102216285B (zh) * 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
BR112015029495A2 (pt) 2017-07-25
ZA201508396B (en) 2019-04-24
PH12015502611A1 (en) 2016-02-29
KR20160013188A (ko) 2016-02-03
JP2016520115A (ja) 2016-07-11
WO2014191737A1 (en) 2014-12-04
AU2014272867A1 (en) 2015-12-10
EA201592108A1 (ru) 2016-07-29
US9579319B2 (en) 2017-02-28
EP3004078A1 (en) 2016-04-13
IL242515A0 (en) 2016-02-01
CA2912208A1 (en) 2014-12-04
CN105431421A (zh) 2016-03-23
GB201309508D0 (en) 2013-07-10
HK1217492A1 (zh) 2017-01-13
WO2014191736A1 (en) 2014-12-04
US20160113928A1 (en) 2016-04-28
SG11201509580PA (en) 2015-12-30

Similar Documents

Publication Publication Date Title
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
PH12020500195A1 (en) Pyrimidinones as factor xia inhibitors
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12017502141A1 (en) Compounds and their methods of use
NZ716392A (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MA39824A (fr) Composés azole amido-substitués
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
TW201613928A (en) Vinyl compounds as inhibitors for FGFR and VEGFR
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).